18 results on '"González-Lama Y"'
Search Results
2. P1023 Variability in Mesalazine Management for Ulcerative Proctitis Include Doses, Route of Administration and Use of Fecal Calprotectin: Insights from Clinical Practice Across Spain Beyond Clinical Guidelines
3. P263 Influence of Crohn′s Disease phenotype in the retention rate of ustekinumab treatment: SUSTAIN Study
4. P509 Influence of concomitant immunosuppresives in retention rate in Crohn′s Disease patients under ustekinumab in the SUSTAIN Study
5. Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU
6. P545 Deep remission assessed by endoscopy, magnetic resonance or intestinal ultrasound, in refractory Crohn’s disease patients in clinical remission with ustekinumab: a real-life single-centre experience
7. P378 Mucosal healing is achieved in most of the inflammatory bowel disease patients in clinical remission with vedolizumab: a real-life single-centre experience
8. DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study
9. P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study
10. P120 Usefulness of the faecal calprotectin for the diagnosis of inflammatory bowel disease in patients with spondylorarthritis and no digestive symptoms
11. P214 How to incorporate patients preference into ulcerative colitis current clinical management: initial document from a Spanish multidisciplinary steering committee
12. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy
13. P400 Incidence and risk factors associated to Crohn’s disease recurrence after total proctocolectomy with definitive ileostomy: A long-term single-centre experience
14. P216 Inflammatory bowel disease unclassified (IBDU) in real practice: prevalence, clinical course and therapy requirements
15. P100 FAECAL CALPROTECTIN'S UTILITY IN THE PREDICTION OF INFLAMMATORY BOWEL DISEASE (IBD) RELAPSES
16. P105 ORAL AND INTRAVENOUS (IV) IRON IN THE MANAGEMENT OF IRON DEFICIENCY ANEMIA IN INFLAMMATORY BOWEL DISEASE
17. P028 UTILITY OF AZATHIOPRINE METABOLITES DETERMINATION DURING FOLLOW UP OF INFLAMMATORY BOWEL DISEASE PATIENTS AFTER STEROID TREATMENT WITHDRAWAL
18. P060 OPEN-LABEL INFLIXIMAB THERAPY IN CROHN'S DISEASE: A LONG-TERM MULTICENTER STUDY OF EFFICACY, SAFETY AND PREDICTORS OF RESPONSE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.